13th Biosimilars Congregation 2019

#VIbsc

"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

11th & 12th June 2019,
Pestana Chelsea Bridge Hotel,
London UK

AGENDA AT A GLANCE

Key Speakers Include

SUE NAEYAERT
VP Global Government Affairs, Policy and Pharmacoeconomics
Fresenius Kabi SwissBioSim

SHU-YI SU
Statistical Scientist
Novartis

IAN HENSHAW
VP, Global Head of Biosimilar Business Unit
Biogen

MAGNUS BODIN
Director, Market Access Biosimilars
Biogen

CHRISTIAN AGBOTON
Sr Global Brand Medical Director - Global Medical Affairs
Takeda

JOSEPH DUNFORD
European Biosimilar Franchise Manager
Accord Healthcare

FREDRIK SUNDBERG
Director Strategic Customer Relations
GE Healthcare

HANMANT BARKATE
Vice President & Head Medical Services, (India, MEA)
Glenmark (India)

JOSEPH SALAMEH
Medical Lead
Alnylam Pharmaceuticals

STEINAR MADSEN
Medical Director
Norwegian Medicines Agency

DORTHE BARTELS
Senior Strategic Advisor
Amgros

JASJA WOLTHOORN
Manager Bioanalysis
Sanquin Diagnostic Services

LOUIS BOON
CSO
Bioceros

LIZ POLLITT
Director
BPCRCS

LENNEKE DE WINTER
USP Director
Bioceros

CORNELIA ULM
Independent Consultant
Biotec Regulatory Consulting

ROBERT A. JOHNSTONE
Board Member
International Alliance of Patients Organisations

KARL DAVISON
Business Development Officer
NIHR Clinical Research Network

JUSTIN STEBBING
Professor of Cancer Medicine and Oncology, Consultant Oncologist
Imperial College Healthcare NHS Trust

GEORGIA GAVRIILIDOU
Counsel, Food, Drug Medical Device Regulatory Life sciences
Sidley Austin LLP

Plus many more COMING SOON.....

WHO ATTENDS?

- **25+** Speakers
- **70%** Pharma / Biotech
- **6+** Hours of Networking
- **2** Days
- **1** Golden Opportunity

www.virtueinsight.com

Organized by

Virtue Insight

29 Gary Court,
189 London Road,
Croydon,
Surrey CR0 2DR

+44-2036120886

info.uk@virtueinsight.com

13th Biosimilars Congregation 2019

"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

11th & 12th June 2019,
Pestana Chelsea Bridge Hotel,
London UK

"I think the event was great and really threw insight on positioning biosimilars vis a vis other drugs on the regulatory side in India and World and what are challenges faced by industry as well as government and also regulators It was a great learning"

Head – Medical Affairs, Wockhardt

AGENDA AT A GLANCE

BRONZE SPONSOR

sartorius stedim biotech

SUPPORTED BY

ConferenceLocate.com
bookmytrainings.com India's No.1 Training Market Place
THE PHARMA TIMES.in www.thepharmatimes.in
ManuscriptEdit
Bio Based Press
Automation-review

Organized by

Virtue Insight

29 Gary Court,
189 London Road,
Croydon,
Surrey CR0 2DR

+44-2036120886

info.uk@virtueinsight.com

13th Biosimilars Congregation 2019

"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

11th & 12th June 2019,
Pestana Chelsea Bridge Hotel,
London UK

"Excellent workshop. It did meet our expectation in term of complete representation of the biosimilar development"

Senior Manager, Regulatory Affairs Sanofi

AGENDA AT A GLANCE

CONFERENCE INTRODUCTION:-

The development of the Biosimilars market is growing exponentially with the industry forecast to be worth $25 billion by 2020. The global biosimilar market is estimated to register a CAGR of 39.53% over the forecast period of 2017-2023. The growth in the market may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics coupled with the patent expiration of the many blockbuster biologic drugs. By 2018, biologics worth more than US$68 billion annual sales will lose patent protection. Due to structural complexity of the biosimilar drugs, multi-layered manufacturing and risk of immunogenicity, separate regulatory pathways have been drafted to introduce them into the market. Increasing investment by the companies for the development of biosimilars will also be the key factor driving the market.

Our 13th Biosimilars Congregation 2019 will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems. Beyond a comprehensive outlook of key European market access policies, our speakers will outline the key recent developments in regulatory science and regulatory policy in the EU and other international jurisdictions. Special emphasis will be placed on strengthening the link between regulators and medical communities as an essential basis for greater understanding and acceptance of biosimilar medicines. This Biosimilars conference will focus on multiple aspects of Biosimilar product development to successfully deliver safe, Biosimilar products to the market place. By attending this conference, you will gain a comprehensive outlook on the key issues surrounding Biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.

It gives me great pleasure in welcoming all of you to the Virtue Insight's 13th Biosimilars and Congregation 2019.

KEY THEMES DISCUSSED IN THIS CONFERENCE:-

- Strategies for market access and expansion by identifying key changes and future projections
- Consequences of Brexit on Biosimilars
- Current Challenges and Opportunities for future- Strategies in developing Biosimilars
- A Clinician's Guide to Biosimilars in Oncology: understanding the Science of Extrapolation and Interchangeability
- Biosimilars – Pricing & Market access - Bringing it faster into market
- GMP, GCP, QC & R&D
- Current challenges and opportunities - strategies to develop Biosimilars
- Payer perspective on biológics and Biosimilars
- Biosimilar Interchangeability: The newest regulation
- Biosimilar - Physicians and Patients perspective
- CMC, Preclinical and clinical considerations for Biosimilars and Follow-on Biologics
- Impact of Technology
- Commercial landscape & market access for Biosimilars: Predicts to prepare for a suceesful tomorrow
- Hear case studies on biosimilars drug development from pre-clinical to clinical and the various testing required such as immunogenicity and bio-similarity tests
- Research-based industry Biosimilar strategies
- Considerations for the analytical similarity assessments when designing a Biosimilar development program
- Determining the right investments & potential returns from Biosimilars
- Latest developments in regulation to increase speed of entry and compliance
- Future of next generation biosimilars
- Be part of a major networking opportunity

AN EVENT TO VOW

Get more from the event, enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference. Whether you are on the branded or generic side, you cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the first to traverse the pathway. Devise an immediate action plan for your biosimilar prosecution and litigation strategies in light of the barriers to entry, research and development costs, and regulatory hurdles, which are balanced against an enormous potential for increased profit margins.

WHY EXHIBIT?

Make Sales
Debut new products
Profile your brand
Meet new business partners
Develop key relationships
Educate pharma and biotech companies

WHO WILL YOU MEET

CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:

Biopharmaceuticals/ Biotherapeutics, Follow on Biologics/Follow on Proteins/Biosimilars, Biologics/Biotechnology/ Biogenerics, Legal Affairs, Intellectual Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Pharmacovigilance, Drug Safety & Risk Management, Quality Affairs/ Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Development, Business Operations, Scientific Affairs, Commercial Affairs, Marketing

VENUE

Pestana Chelsea Bridge Hotel

Address: 354 Queenstown Rd,
London SW8 4AE, UK

Phone: +44 20 7062 8000

MAP & DIRECTIONS

Organized by

Virtue Insight

29 Gary Court,
189 London Road,
Croydon,
Surrey CR0 2DR

+44-2036120886

info.uk@virtueinsight.com

13th Biosimilars Congregation 2019

"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

11th & 12th June 2019,
Pestana Chelsea Bridge Hotel,
London UK

"It was a splendid show yesterday, and esp with you and Sid managing the whole show so smoothly, was very well seen. Virtue Insight Staff were very helpful all through-out"

Director, VIaTAL Pharma Consulting

AGENDA AT A GLANCE

DAY ONE - 11th June 2019

08:30 – **Coffee and registration –** An opportunity to meet and network with your conference colleagues.

09:20 LOUIS BOON
CSO
Bioceros

Chairperson opening remarks

MARKET OVERVIEW & ANALYSIS

09:30 FREDRIK SUNDBERG
Director Strategic Customer Relations
GE Healthcare

Bioprocessing Innovation & Novel Analytical Strategies to Improve Biosimilar Development

- Market Overview & Current Trends.
- Process Intensification and Accelerating Time-to-Market.
- Novel Assay Approaches to Establish Bio-similarity

PAYER'S PERSPECTIVE

10:10 MAGNUS BODIN
Director Market Access Biosimilars
Biogen

Commercialization of Biosimilars in Europe: The anti-TNF success story

- The evolution of the European biosimilar landscape
- The anti-TNF journey from infliximab to etanercept to adalimumab
- Is there a perfect system to drive the uptake of biosimilars?

10:50 – **Morning Coffee/Tea & Discussion**

CHALLENGES & OPPORTUNITIES

11:20 **Keynote Panel Discussion: Current Challenges and Opportunities for future- Strategies in developing Biosimilars**

- Latest developments, Trends and Future of Biosimilars
- Current Challenges and Research trends in Biosimilars & Biologics
- Issues to overcome to increase uptake of biosimilars
- Generate enough interest and enthusiasm for biosimilars
- Lack of stakeholder confidence – what does this lead to?
- Consequences of Brexit on Biosimilars

Moderator:

LOUIS BOON
CSO
Bioceros
Panellists:

IAN HENSHAW
VP, Global Head of Biosimilar Business Unit
Biogen

SHU-YI SU
Statistical Scientist
Novartis

JOSEPH DUNFORD
European Biosimilar Franchise Manager
Accord Healthcare

12:00 STEINAR MADSEN
Medical Director
Norwegian Medicines Agency

From biosimilars to biogenerics?

- Switching and interchangeability
- Are «generic prices» sustainable?
- Is there a future for new biosimilars?

12:40 – **Networking luncheon**

13:50 JASJA WOLTHOORN
Manager Bioanalysis
Sanquin Diagnostic Services

Biosimilars: what can we learn from real life data?

- Discuss cohort studies
- Show data we acquired on biosimilars, ie infliximab
- How do we validate originator assays for biosimilars
- To support biosimilar PK/PD post-marketing?
- Support acceptance of your biosimilar by offering TDM

14:30 SHU-YI SU
Statistical Scientist
Novartis

Statistical Considerations for Analytical Biosimilarity Assessments

15:10 – **Afternoon Tea/Coffee**

Organized by

Virtue Insight

29 Gary Court,
189 London Road,
Croydon,
Surrey CR0 2DR

+44-2036120886

info.uk@virtueinsight.com

13th Biosimilars Congregation 2019

"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

11th & 12th June 2019,
Pestana Chelsea Bridge Hotel,
London UK

"All the topics picked up very good and were pretty informative. The panel discussions brought very nice views and insights on agenda points"

BUSINESS DEVELOPMENT & PM, LUPIN BIOTECH

AGENDA AT A GLANCE

DAY ONE - 11th June 2019

COMMERCIALISATION & MARKET ACCESS

15:30 **Panel Discussion: Commercial landscape & market access for Biosimilars: Predicts to prepare for a successful tomorrow**

- Comparison of US/EU biosimilar developments, policies and guidelines
- The impact of Biosimilars on the competitive landscape of biological products
- Challenges and obstacles faced by manufacturers in developing biosimilars
- Bringing the next generation of Biosimilars to the market
- Ensuring market access and reimbursement
- Evidence generation will be the key to future success
- Stakeholders approach in successfully bringing Biosimilars to the market

Moderator:

LOUIS BOON
CSO
Bioceros

Panellists:

MAGNUS BODIN
Director Market Access Biosimilars
Biogen

JASJA WOLTHOORN
Manager Bioanalysis
Sanquin Diagnostic Services

JUSTIN STEBBING
Professor of Cancer Medicine and Oncology, Consultant Oncologist
Imperial College Healthcare NHS Trust

KARL DAVISON
Business Development Officer
NIHR Clinical Research Network

16:10 – Chairperson's closing remarks and end of conference day one

16:20 - 17:30 **Networking Drinks - Take your discussions further & build new relationships in a relaxed & informal setting**

NETWORKING DRINKS

Meet with your industry peers for a relaxed drink at the end of day one

FOR DELEGATE REGISTRATIONS:-

Our potent conference agenda delivering the latest information and the world class leaders as speakers attract delegates to attend from around the world. We aim for our attendees to be equipped with knowledge of latest developments & enable them to network with the industry key personnel.

Delegate Registration - delegate.uk@virtueinsight.com

Organized by

Virtue Insight

29 Gary Court,
189 London Road,
Croydon,
Surrey CR0 2DR

+44-2036120886

info.uk@virtueinsight.com

13th Biosimilars Congregation 2019

"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

11th & 12th June 2019,
Pestana Chelsea Bridge Hotel,
London UK

"The programme and the format were very good and the atmosphere provided great encouragement for the networking. It was timely organised allowing the participants to exchange opinions on very recent regulatory changes in the US and the EU"

Scientific & Regulatory Director, Regem Consulting Ltd

DAY TWO - 12th June 2019

08:30 – **Coffee and registration** – An opportunity to meet and to network with your conference colleagues.

09:20 **LOUIS BOON**
CSO
Bioceros

Chairperson opening remarks

PATIENT VIEWPOINT

09:30 **ROBERT A. JOHNSTONE**
Board Member
International Alliance of Patients Organisations

How to make Research& Healthcare better; The patient viewpoint

10:10 **SUE NAEYAERT**
VP Global Government Affairs, Policy and Pharmacoeconomics
Fresenius Kabi SwissBioSim

"Biosimilars and policies that help uptake or not"

10:50 – **Morning Coffee/Tea & Discussion**

BUSINESS MODELS

11:20 **CHRISTIAN AGBOTON**
Sr Global Brand Medical Director - Global Medical Affairs
Takeda

JOSEPH SALAMEH
Medical Lead
Alnylam Pharmaceuticals

Biosimilars: Are biologics becoming a commodity? A medical perspective.

- What is needed (efficacy, safety), how to differentiate?
- The challenges of not being the first biosimilar on the market: how to tackle?
- Interchangeability, Education of physicians, Real world evidence data generation, Tender dossiers
- Strategic thinking: biosimilars, a final destination or the beginning of the journey?

12:10 **DORTHE BARTELS**
Senior Strategic Advisor
Amgros

The Biosimilar uptake of biosimilars in Denmark. What's the secret?

- The uptake in Denmark of biosimilars has been both very high and also extremely quick.
- Involvement of many different stakeholders has played a very important roll.
- What can anybody learn from Denmark and will it be possible to copy?

12:50 - **Networking luncheon**

CLINICAL

14:00 **HANMANT BARKATE**
Vice President & Head Medical Services, (India, MEA)
Glenmark (India)

What Physicians' want to know about Biosimilars

- Current level of understanding of biosimilars among different Specialities of physicians
- Need gap of understanding Biosimilars among Physicians
- Understanding of Chemical vs Biologics/Biosimilars, Biosimilarity: Totality of Evidence, Rationality of extrapolation of data, Interchangeability, Regulatory approval process etc.

14:40 **LENNEKE DE WINTER**
USP Director
Bioceros

Using SPOT™ and SLIM™ technology and upstream process modulation to reduce cost of goods of biosimilars

- Increase specific productivity using SPOT™
- Increase specific productivity and biosimilar product quality using upstream process modulation
- Reduce process issues using SLIM™
- Reducing cost of goods of biosimilars

15:20 – **Afternoon Tea/Coffee**

REGULATION OVERVIEW & UPDATE

15:40 **Panel Discussion: The developing regulatory frame work in advanced and developing markets**

- Market and regulatory developments in the Europe and globally
- Predicting the post Brexit changes in biosimilars regulation in UK
- EMA's act on switching & interchangeability?

Organized by

Virtue Insight

29 Gary Court,
189 London Road,
Croydon,
Surrey CR0 2DR

+44-2036120886

info.uk@virtueinsight.com

13th Biosimilars Congregation 2019

"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

11th & 12th June 2019,
Pestana Chelsea Bridge Hotel,
London UK

"The Biosimilars Congregation proved to be an insightful range of presentations which covered the most important aspects of the biosimilars field. I'd recommend it to all stakeholders, manufacturers and regulators alike, who wants to network and gain more up-to-date knowledge in this exciting business area of biologics"

Director, Corporate Business Development, CMC Biologics A/S

DAY TWO - 12th June 2019

- How regulators, payers and policy makers take initiatives to make healthcare more sustainable
- Collaboration with HTA's for patients benefit
- CMC regulatory considerations for Biosimilar products development
- Regulatory changes necessary to maximize biosimilars potential
- The way forward

Moderator:

LOUIS BOON
CSO
Bioceros

Panellists:

CORNELIA ULM
Independent Consultant
Biotec Regulatory Consulting

LIZ POLLITT
Director
BPCRCS

GEORGIA GAVRIILIDOU
Counsel, Food, Drug Medical Device Regulatory Life sciences
Sidley Austin LLP

16:20 - 16:30 **– Chairperson's closing remarks and end of 13th Biosimilars Congregation 2019 conference**

13th Biosimilars Congregation 2019

"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

11th & 12th June 2019,
Pestana Chelsea Bridge Hotel,
London UK

"The presentations were informative and the panel discussions engaging, covering key and important topics of debate. The food and wine reception were excellent and allowed for relaxed networking opportunities"

Director, Voisin Consulting Life Sciences

AGENDA AT A GLANCE

FLOOR PLAN - Book your stalls now before they run out !!!



1 sartorius stedim biotech

4

7

2

5

8

3

6

Note :- The floorplan is subject to change at the discretion of the organisers.

Organized by

Virtue Insight

29 Gary Court,
189 London Road,
Croydon,
Surrey CR0 2DR

+44-2036120886

info.uk@virtueinsight.com

13th Biosimilars Congregation 2019

"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

11th & 12th June 2019,
Pestana Chelsea Bridge Hotel,
London UK

"Well done, most of the speakers selected for the conference were excellent and there was informative as well as participative discussion"

MANAGER - BD & PROGRAM MANAGMENT, LUPIN

For Multiple Bookings - Photocopy this form and send it to delegate.uk@virtueinsight.com; Tel:+44 2036120886

Delegate Details:

Title Mr ☐ Mrs ☐ Ms ☐ Dr ☐

First Name

Surname

Company

Position

Address

Pincode

Telephone

Fax

Email

How to Pay
(Choose one of the following payment options)

RESERVATION PRICING:

Standard Rate

1 Delegate @ £1150 + VAT

3 Delegates @ £2300 + VAT

PAYMENT:

Please send me a VAT invoice ☐

I enclose a cheque for £

Please charge my card £

Card Number ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Security No ☐☐☐☐

Expiry Date ☐☐☐☐☐

Cardholder's Name

Cardholder's Registered Address

Signature

Our purchase order no.is

Payable to Virtue Insight Events Ltd

Card type: Visa ☐ Mastercard ☐ Maestro ☐ Amex ☐

FOR BANK TRANSFER:

Account Name - Virtue Insight Events Ltd

Account Number - 53278603

Bank Name - Barclays Bank PLC **Sort Code -** 20-84-20

SWIFT Code: BARCGB22 **IBAN Code:** GB36BARC20842053278603

ROUTING Code: 026002574

Special Offer:

3 for 2 Offer

*Only few more seats left

TERMS AND CONDITIONS:

Payment terms (Delegates/Attendees):

We require the full amount to be paid before the conference. We may refuse entry if the payment is not paid in full before the event.

Payment terms (Sponsors/Exhibitors):

100% of the sums owed to be paid within 30 days of receipt of invoice (no later than week before the event in case invoice sent with less than 30 days duration).

The Organiser reserves the right to refuse entry to a Sponsor/Exhibitor who has not settled their invoice in full prior to the event. Valid credit card details will be provided by the Sponsor/Exhibitor on receipt of invoice and kept as guarantee until the Organiser receives payment. If payment is not received within 5 days after the event, the Organiser reserves to debit the full amount of the invoice from the credit card provided.

If sponsorship package includes pre-event activity such as brochure/ web promotion etc., the Organiser is entitled to an advance payment of up to 50% of total package at date of invoice.

Cancellations:

Delegates/sponsors/exhibitors/vendors are subject to the following charges and refunds upon withdrawal or cancellation. Between 2-3 month's prior 75% cancellation fee/ 25% refund. Less than 2 months prior to the event Full cancellation fee / No refund.

Administration Fee:

If you cancel your participation (once confirmed) and haven't paid the attendance fee you will still be liable to pay 50% of the attendance fee as we would have already paid to the hotel/venue for your participation (which is non-refundable).

Presentations:

If you cannot attend the conference, you can still purchase the presentations for £400 + VAT.

To view our full T&C,s please visit the link below
https://www.virtueinsight.com/terms-and-conditions/

Organized by

Virtue Insight

29 Gary Court,
189 London Road,
Croydon,
Surrey CR0 2DR

+44-2036120886

info.uk@virtueinsight.com